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Abstract: Needle sharing has become an important factor in the prevalence of HIV and viral
hepatitis rates as injection drug use of illicit substances, such as heroin and prescription opioids,
has increased across the United States. Kentucky, much like the rest of the nation, has also been
devastated by the recent surge of injection drug use. In 2010, drug overdose rates ranked
Kentucky as the third highest state in the nation. Hepatitis B (HBV) and Hepatitis C (HCV) rates
within Kentucky have been consistently higher than the national rate since 2007 and 2003,
respectively. Hospital discharge costs related to HCV infections have increased by $167 million.
In response to this public health problem, the Commonwealth of Kentucky passed Senate Bill
192 (KY SB 192), a comprehensive drug policy with a goals to mitigate the spread of HIV and
viral hepatitis. Provisions of the bill include harsher penalties for heroin trafficking, additional
allocation of funds for addiction treatment, legal immunity for reporting a drug overdose victim,
an increase in the availability of Naloxone, and authorization of needle and syringe exchange
programs (NSEP). KY SB 192 is a multifaceted drug policy, the needle exchange provision was
highly debated and embodies the four characteristics of a morality policy: marked by
controversy, symbolic nature, the policy attracts a diverse policy community, and enduring
controversy. The implementation of NSEP in the state of Kentucky carries the following
projections: An average decrease of 1 to 6 HIV cases per year and an approximate annual decline
in rate by 0.04 to 0.50 per 100,000 (or 1.8 – 22.1 cases per 100,000) for HCV. This amounts to
approximately $2 million in cost savings for both HIV and HCV treatment.

I. Introduction
Injection drug use (IDU) is an effective route of transmission for blood-borne pathogens,
primarily HIV, Hepatitis B (HBV), and Hepatitis C (HCV). Transmission occurs when a person
uses a contaminated syringe without sterilizing it. Needle sharing has become an important factor
in the prevalence of HIV and viral hepatitis rates as injection drug use of illicit substances, such
as heroin and prescription opioids, has increased across the United States. One third of people
who inject drugs (PWID) share needles and account for approximately 9%–12% of new HIV
cases and 50% of new hepatitis C cases in the country.1, 2 Kentucky, much like the rest of the
nation, has also been devastated by the recent surge of injection drug use. In response to this
public health problem, the Commonwealth of Kentucky passed Senate Bill 192, a comprehensive
drug policy with a goals to mitigate the spread of HIV and viral hepatitis. A policy analysis of
this legislation focusing on the communicable disease aspect will be conducted to develop an
understanding of the bill, its health outcomes associated with injection drug use, and demand for
harm reduction interventions within the state of Kentucky.

II. Severity of the Problem
Kentucky Drug Overdose Hospitalization and Death Rates
According to the CDC, “the risk for acquiring and transmitting infectious diseases in a
population is a reflection of the prevalence of a given infection in the population, the efficiency
of transmission of the organism, and the burden of infectious diseases and patterns of the risk
behaviors in which that population engages.”1 Therefore, trends related to drug use, HIV, HBV,
and HCV rates will be examined to substantiate evidence of the problem within Kentucky.
Overdose deaths and hospitalizations related to illicit drug injection use have steadily increased

over the last several years. Drug overdose rates (per 1,000) increased from 15.3 in 2005 to 23.6
in 2010, ranking Kentucky as the third highest state in the nation.3 Heroin contributed to a 207%
increase in overdose deaths and 197% increase in emergency department visits from 2011 to
2012.4 Furthermore, a 900% increase in heroin-related overdose hospitalizations was reported for
years 2002 to 2012.4 As mentioned earlier, injection drug use is not exclusive to heroin;
intravenous use of prescription opioids have contributed to Kentucky’s problem just as much, if
not more, than heroin has.

HIV and Viral Hepatitis among PWID
New HIV diagnoses in Kentucky have remained fairly stable from 2009 to 2013 (see
Figure 1). However, the highest concentration of infections are in three areas of the state:
North/Central Kentucky (49%), Bluegrass/Central Kentucky (19%), and Northern Kentucky
(8%).5 The percent of diagnoses with injection drug use as the transmission route range between
5%-8%. The concentration of cases within age groups vary each year, but the age group 45-54
years is continually among the higher numbers (see Figure 2).
In regards to Viral Hepatitis B and C, increases in rates have been more significant.
Hepatitis C rates within Kentucky have been consistently higher than the national rate since
2003; however, a more dramatic increase occurred from 2009 to 2013 as rates increased from 1.5
to 5.1 (see Fig. 3). Emergency room discharges for HCV increased from 3,821 cases in 2009 to
6,175 cases in 2012 and a $12.5 million increase in associated costs; inpatient cases increased by
62% and discharge costs increased by over $167 million.4 Hepatitis B rates have been
increasingly higher than the national rate since 2007 with a 133% increase from 2009 to 2013
(see Fig 4). The proportion of PWID and population specifics of this data set are unknown, but a

CDC Morbidity and Mortality Weekly Report (MMWR) from May 2015 showed trends of new
HCV cases correlating with opioid injections and substance abuse treatment admissions in four
states of the central Appalachian region that includes Kentucky. From 2006 to 2012, surveillance
data for these states showed a 364% increase in HCV infections among people aged ≤30 years,
with 76% of the cases being attributed to injection drug use from both heroin and prescription
opioids.6 Among all treatment admission in the four states, the proportion of patients reporting
any opioid injections increased by 12.6%.6 Although HIV rates in Kentucky are comparatively
low, the increase of acute Hepatitis B and C raise concerns about the potential increase in HIV
diagnoses, due to recent outbreak in neighboring state Indiana.7

III. Solution
Kentucky Senate Bill 192 is a comprehensive bipartisan bill that covers many facets of
drug addiction. Provisions of the bill include harsher penalties for heroin trafficking, additional
allocation of funds for addiction treatment, legal immunity for reporting a drug overdose victim,
an increase in the availability of Naloxone, and authorization of needle exchange programs.8 The
bill was introduced in state Senate on February 13, 2015 and signed into law by the governor on
March 25, 2015. The bill contained an emergency clause that makes the law take effect
immediate upon passage. While all of these provisions are intended to work together to protect
public health, this policy analysis will focus on the solutions addressing the communicable
disease problem via the needle exchange program and its projected impact. In addition to an
overview of some provisions of the bill, the analytical dimensions in this analysis include
projected outcomes and effects on the injection drug use population, associated costs, support
and opposition, and any unintended consequences.

Provisions of the Bill

Additional Funding for Addiction Treatment
Additional funds will be available for drug treatment programs. Effective for FY 20152016, $10M will be allocated from the General Fund Surplus Account or the Budget Reserve
Trust Fund Account to substance abuse treatment, community mental health centers, and
Kentucky Agency for Substance Abuse Policy (KY-ASAP) and programming. 8 Some of the
KY-ASAP programs outlined in the bill are: substance abuse and behavioral health treatment in
detention centers; residential treatment services to pregnant women to address neonatal
abstinence syndrome; and purchase of FDA-approved extended release treatment to prevent
relapse. Under this bill, this funding is referred to as necessary government expenses as its
purpose is to make treatment more widely available for those who are seeking help. In addition
to the immediate $10 million funding, the addiction treatment system will receive $24 million
annually.

Good Samaritan and Naloxone Provisions
The “Good Samaritan” provision of this policy is an important way to save lives by
administering Naloxone to prevent opiate overdose. If someone is experiencing an overdose or is
with someone who is, there will be no charge or prosecution for possession of a controlled
substance and/or drug paraphernalia if emergency medical assistance is sought. There will be
legal immunity to those who also stay with the person overdosing until medical assistance
arrives. If available, contact information for the person who requested medical assistance shall be

reported to the local health department and the health department should use this information to
offer referrals for substance abuse treatment.
Licensed health care providers, including pharmacists, can prescribe or dispense
Naloxone. First responders, including an agency, peace officer, firefighter, paramedic,
emergency medical technician, school employee, or family member of an addict may receive a
prescription for Naloxone and administer for opiate-related overdoses. Any dispensing of this
drug must be done only under physician-approved protocol and there will be immunity from civil
and legal liability for the administration of Naloxone if done in good faith.

Authorization of Needle Exchange Programs
In effort prevent further HIV and viral hepatitis infections, the state has explicitly
authorized health departments to implement a needle exchange program. A needle syringe
exchange program (NSEP) is an evidence-based harm reduction strategy for PWID where they
may exchange used, or potentially contaminated, needles for sterile ones. These programs
promote safer injection practices, provide proper disposal of used needles, and reduce the spread
of HIV, viral hepatitis, and other blood-borne infections. NSEP is not a new public health
intervention. In the mid-1980s, nations worldwide determined that the promotion of safer
injection practices for PWID could prove to be an HIV and Hepatitis B and C control factor. This
led to the first needle exchange program being implemented in 1984 in Amsterdam. As this
program became a cornerstone of HIV prevention in the country, NSEPs have globally expanded
mainly through community-based nongovernmental organizations and help from international
organizations such as World Health Organization (WHO) and Joint United Nations Program on
HIV/AIDS (UNAIDS).9 In the United States, federal funding for NSEPs are banned, but states

are able to implement legislation that allows needle exchange by decriminalizing free
distribution of syringes from their drug paraphernalia laws and explicitly authorizing needle and
syringe exchange programs.
KY SB 192 explicitly authorizes local health departments to operate NSEPs as substance
abuse treatment outreach programs by amending KRS 218A.51, a statute that deems syringes
and needles as drug paraphernalia. This makes Kentucky one of the fourteen states to have
removed syringes from their definition of drug paraphernalia and one of the 17 states to
authorize needle exchange programs to date.10 Under this legislation, the program is named
Harm Reduction and Syringe Exchange Program (HRSEP). Local health departments must have
the consent from the board of health, the legislative body of the city in which the program would
operate, and the legislative body of the relative county. Permission from the board of health may
be revoked at any time. 8 In addition to state and local authorization, health departments must
first conduct a community needs assessment before presenting request to board of health. Due to
the amendment, needles and syringes exchanged at the program will not be considered as drug
paraphernalia.

Efficacy
Because this legislation is less than a year old at the time of this paper, efficacy of NSEPs
and projected outcomes for the Kentucky population will be discussed. A large body of research
associates NSEPs with the reduction in HIV transmission among PWID, both internationally and
within the United States.
A study that examining the global context of NSEPs reported the reduction of HIV
infections in a variety of forms. For example, India experienced an HIV prevalence reduction

among PWID who participated in NSEPs from 80.7% to 58% over a three year period. It’s
important to note that Asia has the largest injection drug use in the world and India’s experience
with NSEPs is a great example of the program’s potential. Another example included in the
study is the implementation of New Zealand’s first NSEP in 1987. HIV infection rates fell by
18.6% annually and cities without NSEP had an HCV prevalence of 75% among injection drug
users, while cities with NSEP had prevalence of 60%. Additionally, a government report
concluded that NSEP aided in preventing 25,000 HIV infections and 21,000 HCV infections by
2001; this saved New Zealand $35 million in treatment costs. 9
The effectiveness of needle and syringe exchange programs have been evaluated on a
national level as well. The first legal needle exchange program in the U.S. was operated in
Tacoma, Washington. Initially, the exchange program was operated by a former drug counselor
whose main concern was the risk of transmission of HIV among PWID. Two months later, an
evaluation was performed on the exchange program that led to funding from the Tacoma-Pierce
County Health Department in 1989. In November of 1992, the Washington State Supreme Court
deemed syringe exchange as legal; while not a comprehensive drug policy per se, the court
elected it to be an HIV prevention measure.11
An interview study was done on the Tacoma needle exchange participants to report on
the operations and potential effectiveness of the program. The study was done over a span of
fourteen months from October 1988 to December 1989 and involved 204 participants. The
results of the questionnaire showed a significant reduction (-11 to -38 mean change) in average
number in injection practices per month for those who borrowed and/or rented syringes, loaned
syringes to other IDUs, and an increase (+36 mean change) in those who used bleach to disinfect

syringes; furthermore, these results were not significantly associated with gender, race, or most
frequently injected drug.11
A study conducted by Beth Israel Medical Center on New York City injection drug users
found a 41% decline in HIV prevalence from between 1990 and 2001.12 Additionally, the
Hepatitis C prevalence fell by 27% during the same period. In this time period, there was
exceptional coverage by NSEPs that were widely expanded throughout the area. Approximately
250,000 to 3 million needles were exchanged annually. This decline in HIV rates let to an overall
decrease in injection drug use as a risk factor for HIV in New York State.12
It is important to note that the passing of this bill comes at the heel of an HIV outbreak in
Scott County, Indiana. Scott County is a rural community in southeast Indiana approximately 30
miles outside of Kentucky. Like Kentucky, Indiana declared a state of emergency after the
largest-ever HIV outbreak in the state. From November 16, 2014 to Mach 16, 2015 there were 75
new cases of HIV infection, many of whom were co-infected with HCV.7,13 These diagnoses
were associated with the intravenous use of prescription opioid Opana. Although NSEPs are
illegal in the state of Indiana, Governor Mike Pence authorized a short-term, 30-day, needle
exchange program that began operation in April, 2015. Since then, over half of PWID have used
the service and the spread of disease has been contained as HIV rates decreased and remained
non-existent during the month of July, 2015.
Based on model projections from a study done by Degenhardt et al., efficacy is dependent
upon recruitment rates of participation in NSEP. Using the model, if there is a 50% percent
yearly recruitment rate, leading to 51% of PWID participating in NSEPs, then this could lead to a
20% decrease in HIV incidence after five years.14
Cost

There are many costs and resources associated with NSEPs. Of course, cost per unit of
service will vary depending on where and how the needle exchanges operate (mobile, stationary,
etc.). Costs associated with staffing and supplies must be taken into account as well. Due to the
federal ban on syringe exchange programs, staff members who are fully or partially funded by
the federal government may not participate in the needle exchange portion of the program. Yet,
this does not prevent them from participation in HIV/STD screening and other referrals to
healthcare. Other expenses that should be considered are staff hours to perform the needs
assessment, the hiring of new staff if necessary, and the training.
The recommended resources needed to implement a syringe exchange program are:


Different sized needles (at least two)



Needle cleaning kit (bottle cap, cotton/filter, clean water bottle, alcohol pads, bleach
bottle, Band-Aids, and instruction manual)



Hazardous waste container for sharp objects (also called a “sharps container”)



Puncture-proof gloves



Condoms and lubricant



Paper bag to hold supplies



Disinfectant solution or spray



Educational materials
o Safe and proper injection techniques
o Information regarding HIV, Viral Hepatitis (HBV, HCV), and other sexually
transmitted infections

It is not uncommon for syringe exchange programs to have these particular resources donated to
them from local businesses and/or community organizations.

The optimal prevention strategy is to use a sterile syringe for every injection. Sterile
syringes are approximately $0.97 to $0.99 and even less when purchased in bulk or at a
discounted/contract rate. It is estimated that an individual IDU injects about 1,000 times per year
and the cost of preventing one HIV case is estimated between $4,000 and $12,000.15, 16 Lifetime
costs for new diagnoses of HIV in Kentucky is over $368,000 per person in 2009.17 For Hepatitis
C, cost is approximately $94,500 for 12 weeks of treatment, not including lab testing and
physician and/or specialist visits.18

Impact
So far in this analysis, Kentucky’s injection drug use problem and severity have been
defined and the solution has been examined with international and domestic research supporting
NSEP efficacy. Yet, the question remains: how will the implementation of needle exchange
programs affect Kentucky?
According to a report by the University of Kentucky Center on Drug and Alcohol
Research, 0.9% of adults 18 years of age and older have used intravenous drugs in their
lifetime.19 As of 2014, approximately 3,402,775 people, or 77%, of the Kentucky population are
age 18 years and older; this provides s a number of almost 30,624 injection drug users in the
state.20 Because one third of PWID share needles, this means 10,208 people are at risk for HIV
and viral hepatitis in Kentucky. Using the data from Figure 1, Kentucky has an average number
of 27 HIV cases with IDU as transmission route per year. For HCV, data from 2008 to 2013
(Figure 3) will be used since that is the time period when Kentucky rates dramatically increased
and were consistently above the national rate. As a result, the average rate of HCV infections per
year is 3 per 100,000.

To move forward with Kentucky efficacy projections for impact, let’s take another look
at the data observed in India, New Zealand, and New York City as previously discussed in the
“Efficacy” section. The numbers used for these projections reflect a population that do not
completely mirror Kentucky. These populations potentially differ in race, gender participation,
socioeconomic status, and geography. However, as previously mentioned, the study in Tacoma
noted the results of their study were not significantly associated with gender, race, or most
frequently injected drug.
Using the total percentage decrease over the number of years indicated in the study, we
get an average percent decrease per year. Applying the data from each study resulted in averages
3.7% and 7.6% decrease in HIV prevalence per year in New York and India, respectively.
Hepatitis C prevalence decreased by an average of 1.3% in New York City and 15% per year in
New Zealand.9 If we apply these findings to project the annual decrease in HIV and HCV
prevalence in Kentucky, we can expect to see an average decrease of 1 to 6 HIV cases per year
and an approximate annual decline in rate by 0.04 to 0.50 per 100,000 (or 1.8 – 22.1 cases per
100,000) for HCV.
With the estimated reduction in disease prevalence comes cost savings projections. After
applying lifetime treatment costs HIV, savings range from $368,000 to $2.2 million per year.
Savings associated with Hepatitis C treatment range from $170,100 to approximately $2 million
per year. With 10,208 people sharing needles, the financial risk for HCV costs amount to
approximately $964 million and almost $3.8 billion for HIV. However, if one sterile syringe is
supplied for each injection per user, the annual cost would be approximately $30.6 million,
which is far less than the financial risk. The cost of prevention outweighs the cost of HIV and
HCV diagnoses and prevents a heavier burden on Kentucky’s health care system.

In addition to sterile syringes, NSEPs provide: sexually transmitted infection (STI)
prevention supplies (condoms, lubricant, etc.); educational material pertaining to overdose
prevention, safe injection practices, and information about HIV and viral hepatitis; HIV and viral
hepatitis testing and counseling; referrals for substance abuse treatment and human resources
(housing, food, etc.); and other ancillary medical services, depending on the program.
Needle and syringe exchange programs also serve as a pathway for treatment for those
who seek it. To reference the Tacoma study, almost half of the people admitted to the methadone
treatment program were referred from the needle exchange service. The Affordable Care Act
requires health insurance policies to provide adequate mental health coverage that include
substance abuse treatment. This becomes an advantage for NSEP participants whom wish to
begin treatment.

Support and Opposition – NSEP as Morality Policy
According to Elizabeth Bowen, NSEP policy is a morality policy that is fueled by
controversy and morality. While KY SB 192 is a multifaceted drug policy, the needle exchange
provision was highly debated and embodies the four characteristics of a morality policy: marked
by controversy, symbolic nature, the policy attracts a diverse policy community, and enduring
controversy.21 The controversy of NSEPs have been evident in the United States as debates have
been based on the morality of drug use behavior and scientific evidence and Kentucky is no
different.

NSEP Policy Marked by Controversy

In morality policies, the importance of scientific evidence is minimized by arguments that
are based on value, whether it be “good vs. bad,” financial, or convenience. Reports from the
Kentucky Office of Drug Control Policy have fueled support in the bill as they reflect the
severity of Kentucky’s current heroin and prescription opioid problem. Despite the need and
research findings from NSEP program evaluations, state senators believed the exchange of free
needles would enable addicts and convey a poor message to youth.

The Symbolic Nature of KY SB 192
The symbolic nature of this bill weighs heavier than the consequences and consideration
of various means to achieve the goals behind it. Politicians believe for this bill to be a “message”
to addicts and dealers in hopes for it to be effective in the battle against heroin. Jessica Padgett, a
supporter who has been arguing for the bill, believed this legislation will take the stigma away
from heroin use and provide families with hope. The primary sponsor of the bill, Senator Paul
Hornback, R-Shelbyville, voted against S.B. 192 due to the needle exchange provision that was
included in the bill. He believed the provision is an enabling factor for addicts.22, 23

Policy Community Roles
Morality policies attract a diverse policy community. Advocacy groups such as People
Advocating Recovery in Northern Kentucky and North Kentucky Hates Heroin have displayed
strong support for NSEP by producing community events for awareness, creating legislative
committees, and public marches at the state capital. Families and loved ones of heroin addicts
have written numerous letters in support. Policymakers’ support for the needle exchange
provision is based on the HIV outbreak in Indiana, and the recent surge in HCV infections within

Kentucky. Support is fueled by the belief that needle exchange programs would not only serve as
a first line of defense against HIV and viral hepatitis, but also as a first point in contact between
addicts and professionals who can offer assistance in recovery. Other community organizations
have mobilized in opposition of the bill. Tennessee faith-based group “Stand in the Gap” has
held several anti-drug rallies in northern Tennessee, Kentucky, and Virginia. This groups
supports the bill, except for the needle exchange provision, concerned that it could do more harm
than good by promoting drugs.

The Enduring Controversy
The passing of this bill has not ended debate. Morality policies, such as this one, often
remain confidential. After Governor Steve Beshear signed the bill into action, doubts remained
among Kentucky residents and policymakers. The arguments and concerns expressed in
opposition of the bill are the same in the aftermath. There are some who believe the NSEP
provision serves as an enabling factor, despite its potential to prevent blood-borne infections.
Louisville-Metro NSEP does not require injection drug users to exchange used needles. State
Sen. Whitney Westerfield, R-Hopkinsville believes this undermines the law’s intention because
it promotes intravenous drug usage. In Louisville-Metro’s defense, exchange is encouraged in
the program; but because the goal is to prevent infections by distributing sterile syringes, free
needles need to be handed out since many addicts share one needle and the requirement of an
exchange may deter participation.24, 25

Social Construction of People Who Inject Drugs

Another factor causing debate is the social construction of the target population addressed
in this policy. According to Schneider and Ingram, the social construction of a target population
has an influence on policy agenda and reasons that constitute policy choices.26 There are four
social constructions in policy: Advantaged, Contenders, Dependents, and Deviants. Groups who
are considered Advantaged are viewed as good and intelligent and are respected. Contenders are
suspicious and vigilant towards government and should be treated with caution. Those who are
Dependents are pitied, helpless and have responsibilities that should be of private interest. As for
injection drug users, they are categorized under the Deviant category. This is a negatively
constructed group that is powerless and should not be treated with respect. Because this group is
viewed as bad people who are responsible for their own difficulties and whose behaviors create
problem for others, policies catered toward this target population typically lack support and/or
endure more resistance to acceptance. Because NSEPs in Kentucky are only authorized if
implemented by public health departments, majority of funding comes from tax payer revenue.
Some concerned citizens believe this conveys a message that the government condones drug use.

Potential Barriers
Accessibility, the covert nature of PWID, and lack of federal funding are some of the
potential barriers of this policy. Adequate needle coverage is essential to the efficacy of this
program and other provisions of the policy. Without adequate access, there are missed
opportunities to provide PWIDs with sterile syringe, link them to substance abuse treatment, or
educate them about the increased availability of Naloxone. Facility and hours of operations play
a major role in coverage, access, and PWID participation.

Louisville-Metro implemented Kentucky’s first HRSEP in June 2015 and within one
month of operation, there have been approximately 300 participants. Twenty percent were tested
for HIV and all had negative results. The number of participants increased to 800 by October
with over 50 people being referred to substance abuse treatment programs.27 Some reasons why
the Louisville-Metro exchange program has a large number of participants is because the
program operates in a mobile unit outside of the health department building six days of the
week.28 First, separating the exchange program from the health department building increases
comfort and decreases stigma. Second, having a fair amount of days and hours of operation
increases the probability of participation. When public health interventions make the service
more accessible, it is more likely to be utilized. Fortunately, Louisville-Metro had the necessary
funds, resources, and staffing to accomplish this. However, other health departments in Kentucky
may not be so lucky. Health departments located in rural areas and/or with smaller budgets may
face difficulty recruiting and retaining participants. Health departments that can only manage to
operate one day a week miss out on outreach and intervention opportunities because coverage is
limited. Another example is the Lexington-Fayette County Health Department needle exchange
program. This program operates within the health department clinic for three hours once a week.
This health department belongs to the second largest city in Kentucky, yet, participation is not
nearly as much as what has been seen in Louisville.
An additional barrier that contributes to the possible shortcomings of other health
departments within Kentucky is the ban on federal funding of NSEPs. On November 4, 1988,
under 42 U.S. Code § 300ee–5, the United States implemented a ban on federal funding of
needle exchange programs. The law states, “None of the funds provided under this Act or an
amendment made by this Act shall be used to provide individuals with hypodermic needles or

syringes so that such individuals may use illegal drugs, unless the Surgeon General of the Public
Health Service determines that a demonstration needle exchange program would be effective in
reducing drug abuse and the risk that the public will become infected with the etiologic agent for
acquired immune deficiency syndrome.”29 Despite five government-commissioned reports
between 1997 and 1997 that provided evidence of NEPs association with preventing HIV
transmission among injection drug users, the ban was upheld, except for a brief lift from 2009 to
2011.30 Not only would lifting the ban allow more funds to be allocated towards NSEPs, but it
could save money by allowing staff whose salary is federally funded to participate in exchange
programs instead of acquiring additional personnel. Without federal funding, it is difficult for
needle and syringe exchange programs to reach their full potential.
According to Kentucky HRSEP guidelines, a unique identifier card is required for
participation. While these cards are for patient tracking and ensuring legal immunity, they are not
meant to be revealing of anyone’s identity. However, out of fear of being identified, this can
make some PWID feel uncomfortable and unwilling to use the available services.
Kentucky S.B. 192 as a morality policy can be perceived as a barrier. The ongoing
controversy of NSEP could prevent adequate expansion of programs. Value-based arguments
and beliefs could prevent legislative bodies from approving health department proposals for a
program. Furthermore, these same arguments may call for appeals and amendments of the NSEP
provision.

Unintended Consequences
There is no evidence of unintended consequences within the United States, such as
increase in drug users, more used needles discarded in the community, and spike in crime rates.

However, this does not negate that unintended consequences can’t occur. As seen in Montreal,
NEPs were associated with higher HIV rates due to a formation of new social networks.31 While
the probability of this happening in Kentucky is small, these inadvertent consequences shan’t be
ignored.

IV. Conclusion
Kentucky Senate Bill 192 is a comprehensive drug policy that tackles the many faces of
substance abuse. Needle and syringe exchange programs are essential for infectious disease
prevention among the injection drug use population. However, no intervention is “one size fits
all.” Every policy and intervention has its advantages and barriers. While there are potential
barriers, there are advantages working in favor of this policy. Exchange programs are an
effective way to link the target population to the healthcare system and other resources. The
explicit authorization of NSEPs through health departments has potential to gain additional trust
of the hidden injection drug use population. This trust in the healthcare system is important
because it increases the likelihood of service utilization.
The increase of heroin and opioid overdose deaths and Hepatitis B and C rates in
Kentucky are indicative of the increase in injection drug use in the state and mirrors the epidemic
across the country. As a result of the NSEP provision, Kentucky can expect HIV prevalence to
decrease by 1 to 6 cases with cost savings up to $2.2 million a year. The state will save a
projected annual $2 million in associated HCV treatment costs and experience a drop in
prevalence by 1.8 – 22.1 cases per 100,000. In order for these projections to become reality, it is
imperative for health departments to provide adequate coverage to reach the target population.

This means state-wide expansion, accessible location and hours, and providing on-site ancillary
services.
There will never be a complete elimination of substance abuse. The combination of
syringe exchange programs, additional substance abuse treatment program funding, and
increased availability of Naloxone is a step in the right direction in controlling the drug problem
within the state of Kentucky.
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Figure 1: HIV cases in Kentucky. All transmission routes vs IDU transmission. Data collected from CDC NCHHSTP Atlas.
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Figure 1: HIV transmission via injection drug use for years 2009-2013. By age. Data collected from CDC NCHHSTP Atlas
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Figure 2. Hepatitis C rates in the United States vs. rates in Kentucky. Years 200-2013. Data collected from CDC NCHHSTP Atlas
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Figure 3: Hepatitis C rates in the United States vs. rates in Kentucky. Years 200-2013. Data collected from CDC NCHHSTP Atlas
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